Bioxodes Chief Medical Officer Hans Warrinnier topped a “lessons learned” list companies shared with the Clinical Leader magazine. May 20 is Clinical Trial Day, and the magazine had asked companies for tips and tricks based on their experiences testing pharmaceuticals in the lab. In the piece, Hans Warrinnier explained how Bioxodes initially struggled to attract enough patients into its BIRCH trial with BIOX-101. “Ischemic stroke is a disease with acute symptoms [but] hemorrhagic stroke often starts more gradually,” Hans said. “Patients tend to come into the hospital later, and sometimes, there wasn’t enough time to register them for the trial.” Bioxodes then amended the trial protocol and changed the maximum intake time to 24 hours – still in line with the biology of the disease, Warrinnier explained.